UK plans gene-synthesis rules to stop AI-built bioweapons
London moved on the AI-bio risk that labs have been warning about, Wall Street's biggest bank put a price tag on the AI buildout, and an acquisition pulled AI-driven biology closer to the factory floor.
The UK government is planning to regulate the use of AI in gene synthesis, part of a push to stop terrorists and other bad actors from using the technology to build biological weapons. Ministers are exploring new biological-weapons legislation that would cover synthetic DNA production, according to people familiar with the matter. The core worry is a lack of global guardrails: AI tools that can design DNA sequences, combined with commercial gene-synthesis services, could let someone order dangerous genetic material without the screening catching it. Screening of DNA orders has so far been mostly voluntary industry practice, which is exactly what a national law would change. It is one of the first concrete regulatory responses to the AI-bio risk anywhere, and it extends London's pattern of moving early on frontier-AI safety — the UK was the first government to run a formal AI safety summit. The details matter here: whether the rules bite at the synthesis step or at the AI-design layer, and whether they set a template other countries copy. What is announced so far is a plan, not a law — but the direction is unmistakable.
Bank of America pledged $250 billion to finance US data centers, energy and core infrastructure by July 2027. The "Critical Infrastructure Finance Initiative" targets digital infrastructure (data centers, computing hardware, chips, telecom), power generation and storage, and core projects like transportation, grid upgrades and critical minerals — delivered through lending, investing and capital-markets activity over an 18-month window. Bank of America joins Morgan Stanley and JPMorgan, each of which has floated roughly $1.5 trillion programs for technology and national-security-critical industries. The pledge is the clearest signal yet that mainstream finance now treats the AI buildout as a durable asset class rather than a hype cycle: the same demand that has driven CoreWeave's backlog past $100 billion is now being underwritten by the largest US banks.
Danish biomanufacturing startup Again acquired Genomatica (Geno), merging AI-driven molecule design with industrial-scale production. Geno, the San Diego company founded in 1998, brings a computational biotechnology platform, more than 1,100 patents and two decades of experimental and scale-up data; Again adds AI-powered bioprocess design and multi-feedstock manufacturing know-how. Terms were not disclosed. The combined company now spans the full arc from pathway discovery to commercial manufacturing, a consolidation that reflects where AI-for-biology is heading: discovery models are commoditizing fast, and the durable value is in whoever can actually scale a process to production. It also lands as the US and Europe push to expand domestic biomanufacturing capacity.
What to watch: whether other governments follow London's lead on gene-synthesis rules — and whether Bank of America's pledge turns into actual data-center deals before the end of the year.
Should AI-driven gene synthesis be regulated like weapons technology? Tell us in the comments.
